Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial
01 nov. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
12 oct. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment Achieved an additional $8 million in research...
Nurix Announces Strategic Collaboration with Seagen Combining Industry Leading Technologies of Targeted Protein Degradation and Antibody-Drug Conjugation to Advance an Innovative New Class of Cancer Therapeutics
07 sept. 2023 07h00 HE
|
Nurix Therapeutics, Inc.
Nurix and Seagen to develop a portfolio of Degrader-Antibody Conjugates (DACs): antibodies that deliver a targeted protein degrader payload to selectively kill cancer cells Nurix to receive a $60...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
31 août 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
13 juil. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations ...
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
14 juin 2023 07h00 HE
|
Nurix Therapeutics, Inc.
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated...
Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
09 mai 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations
17 avr. 2023 14h30 HE
|
Nurix Therapeutics, Inc.
Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix’s lead BTK degrader for the treatment of B-cell malignancies Poster presentation highlights...
Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
13 avr. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation...
Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...